-+ 0.00%
-+ 0.00%
-+ 0.00%

Ocugen Q1 FY26 net loss widens 24.9% to $19.18 million

PUBT·05/05/2026 12:34:04
Listen to the news
Ocugen Q1 FY26 net loss widens 24.9% to $19.18 million
  • Ocugen posted a net loss of $19.18 million, or $0.06 per share, for first-quarter 2026, widening from a $15.35 million loss, or $0.05 per share, a year earlier.
  • Operating loss widened to $17.84 million as operating expenses climbed to $19.37 million, including R&D of $11.26 million.
  • Revenue edged up to $1.53 million from collaborative arrangement revenue.
  • Cash, cash equivalents, and restricted cash totaled $32.2 million at March 31; Ocugen expects $112.1 million at closing of a $115 million private offering of 6.75% convertible senior notes due 2034, extending cash runway into 2028.
  • Enrollment completed for OCU400 retinitis pigmentosa Phase 3 and OCU410ST Stargardt Phase 2/3; rolling BLA submission for OCU400 targeted for Q3 2026, while OCU410 Phase 3 for geographic atrophy targeted to start in Q3 2026 after Phase 2 showed a 31% lesion-growth reduction at 12 months.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocugen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605050832PRIMZONEFULLFEED9713281) on May 05, 2026, and is solely responsible for the information contained therein.